Baker Bros. Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Baker Bros. Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,548,069	Closed	-$45.3M	–	99
2018 Q3	$45.3M	Buy	2,548,069 +270,270	+12%	+$4.64M	0.3%	28
2018 Q2	$31.4M	Hold	2,277,799	–	–	0.24%	32
2018 Q1	$20.7M	Buy	2,277,799 +1,190,476	+109%	+$6.57M	0.18%	43
2017 Q4	$4.65M	Buy	+1,087,323	New	+$5.18M	0.04%	82
2016 Q4	–	Sell	-868,983	Closed	-$2.69M	–	138
2016 Q3	$2.69M	Sell	868,983 -261,594	-23%	-$815K	0.02%	86
2016 Q2	$3.63M	Sell	1,130,577 -565,288	-33%	-$2.07M	0.04%	79
2016 Q1	$5.26M	Hold	1,695,865	–	–	0.06%	73
2015 Q4	$6.8M	Buy	1,695,865 +339,313	+25%	+$1.56M	0.06%	69
2015 Q3	$6.21M	Buy	+1,356,552	New	+$7.1M	0.06%	74

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Baker Bros. Advisors's ECYT Position: Q4 2018 in Review

Baker Bros. Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 2,548,069 shares — an estimated $45.3M sold.

Baker Bros. Advisors first reported a position in ECYT in Q3 2015 and held it in 9 quarters. The position peaked at $45.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Baker Bros. Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Baker Bros. Advisors sold 2,548,069 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $45.3M.
Baker Bros. Advisors first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 9 quarters.
Baker Bros. Advisors's Endocyte, Inc. Common Stock position peaked at $45.3M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.